PE/Cyanine7 anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RM4-5_PECy7_030206
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) PE/Cyanine7 (filled histogram) or rat IgG2a, κ PE/Cyanine7 isotype control (open histogram).
  • RM4-5_PECy7_030206
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) PE/Cyanine7 (filled histogram) or rat IgG2a, κ PE/Cyanine7 isotype control (open histogram).
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100527 25 µg 71€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100528 100 µg 159€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Quispe Calla N, et al. 2016. Sci Rep. 6:37723. PubMed
  2. Xing J, et al. 2021. Cell Reports. 35(12):109205. PubMed
  3. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  4. Du C, et al. 2016. Nat Commun. 7: 11120. PubMed
  5. Nocera D, et al. 2016. J Immunol. 196: 2860 - 2869. PubMed
  6. Gravano D, et al. 2010. PLoS One. 5:e13528. PubMed
  7. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  8. Hastings AK, et al. 2019. iScience. 13:339. PubMed
  9. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  10. Gengenbacher M, et al. 2016. MBio. 7: 00679-16. PubMed
  11. Wang D, et al. 2018. Immunity. 48:659. PubMed
  12. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  13. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  14. Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed
  15. Stegelmeier AA, et al. 2022. Biomedicines. 10:. PubMed
  16. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  17. Choi JY, et al. 2020. Proc Natl Acad Sci U S A. 117:6042. PubMed
  18. Schaller M, et al. 2015. J Leukoc Biol. 98: 601 - 613. PubMed
  19. Bhattacharjee S, et al. 2019. Cell Rep. 28:231. PubMed
  20. Guo Q, et al. 2021. Front Cardiovasc Med. 8:633212. PubMed
  21. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
  22. Si Y, et al. 2020. Sci Adv. 6:eaba0995. PubMed
  23. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  24. Thompson PJ et al. 2019. Cell metabolism. 29(5):1045-1060 . PubMed
  25. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  26. Blankenhaus B, et al. 2014. PLoS Pathog. 10:1003913. PubMed
  27. Kedage V, et al. 2022. MAbs. 14:2040083. PubMed
  28. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  29. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  30. Miyazaki M et al. 2017. Immunity. 46(5):818-834 . PubMed
  31. Ly A, et al. 2020. Cell Reports. 29(8):2257-2269.e6.. PubMed
  32. JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed
  33. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  34. Daniel CJ, et al. 2022. Mol Cancer Res. 20:1151. PubMed
  35. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  36. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  37. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  38. Pishesha N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  39. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
  40. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  41. Carty S, et al. 2014. PLoS One. 9:106659. PubMed
  42. Macdougall CE et al. 2018. Cell metabolism. 27(3):588-601 . PubMed
  43. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
  44. Liu B, et al. 2022. Mol Med Rep. 26:. PubMed
  45. Studniberg SI, et al. 2022. Mol Syst Biol. 18:e10824. PubMed
  46. Ballet R, et al. 2014. PLoS Pathog. 10:1004550. PubMed
  47. Xu X, et al. 2018. J Dermatol Sci. 91:134. PubMed
  48. Riding AM, et al. 2022. iScience. 25:104660. PubMed
  49. Mandal RK, et al. 2021. Cell Reports. 35(6):109094. PubMed
  50. Hirata SI, et al. 2020. Allergy. 75:1939. PubMed
  51. Frohner IE, et al. 2020. Cell Rep. 30:3171. PubMed
  52. Shibuya M, et al. 2021. iScience. 24:103131. PubMed
  53. Macagno M, et al. 2014. J Immunol. 192:5434. PubMed
  54. Laubreton D, et al. 2020. Viruses. 12:00. PubMed
  55. Di Lorenzo A, et al. 2022. Oncoimmunology. 11:2086752. PubMed
  56. Kim D, et al. 2020. Immunity. 53(3):581-596.e5. PubMed
  57. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  58. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  59. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. PubMed
  60. Ryg-Cornejo V, et al. 2016. Cell Rep. 14:68-81. PubMed
  61. Chong WP, et al. 2020. Immunity. 53(2):384-397.e5.. PubMed
  62. Platteel ACM, et al. 2018. Front Immunol. 1.544444444. PubMed
  63. Chryplewicz A, et al. 2022. Cancer Cell. 40:1111. PubMed
  64. Guan D, et al. 2021. Cell Death Dis. 12:431. PubMed
  65. Lai NY, et al. 2020. Cell. 180:33:00. PubMed
  66. Hassan H, et al. 2011. Proc Natl Acad Sci U S A. 108:18330. PubMed
  67. Lau A, et al. 2022. Sci Adv. 8:eabm0142. PubMed
  68. Dietschmann A, et al. 2020. Eur J Immunol. 50:1044. PubMed
  69. C Khouili S, et al. 2020. Cell Rep. 33:108468. PubMed
  70. Campisi L, et al. 2016. Nat Immunol. 10.1038/ni.3512. PubMed
  71. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
  72. Kubli SP, et al. 2019. Nat Commun. 10:2678. PubMed
  73. Okubo A, et al. 2021. Int J Mol Sci. 23:. PubMed
RRID
AB_312728 (BioLegend Cat. No. 100527)
AB_312729 (BioLegend Cat. No. 100528)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 3    Revision Date: 01/29/2013

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD4

  • Biotin anti-mouse CD4

  • FITC anti-mouse CD4

  • PE anti-mouse CD4

  • PE/Cyanine5 anti-mouse CD4

  • Purified anti-mouse CD4

  • PE/Cyanine7 anti-mouse CD4

  • APC/Cyanine7 anti-mouse CD4

  • Alexa Fluor® 647 anti-mouse CD4

  • Alexa Fluor® 488 anti-mouse CD4

  • Pacific Blue™ anti-mouse CD4

  • Alexa Fluor® 700 anti-mouse CD4

  • PerCP anti-mouse CD4

  • PerCP/Cyanine5.5 anti-mouse CD4

  • Brilliant Violet 421™ anti-mouse CD4

  • APC/Fire™ 750 anti-mouse CD4

  • Brilliant Violet 570™ anti-mouse CD4

  • Brilliant Violet 605™ anti-mouse CD4

  • Brilliant Violet 650™ anti-mouse CD4

  • Brilliant Violet 711™ anti-mouse CD4

  • Brilliant Violet 785™ anti-mouse CD4

  • Brilliant Violet 510™ anti-mouse CD4

  • Purified anti-mouse CD4 (Maxpar® Ready)

  • PE/Dazzle™ 594 anti-mouse CD4

  • TotalSeq™-A0001 anti-mouse CD4

  • TotalSeq™-B0001 anti-mouse CD4

  • TotalSeq™-C0001 anti-mouse CD4

  • Ultra-LEAF™ Purified anti-mouse CD4

  • Spark Violet™ 423 anti-mouse CD4 (L3T4) Antibody

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account